Literature DB >> 28645006

Study of intestinal anti-inflammatory activity of Phoenix loureiroi Kunth (Arecaceae) fruit.

Rajan Murugan1, Shanmugam Saravanan2, Thangaraj Parimelazhagan3.   

Abstract

Phoenix loureiroi Kunth belongs to the family Arecaceae, the fruits are widely consumed by Kurumba and Irula tribes of Tamil Nadu (India) and also used to cure intestinal related diseases in folklore medicine. Therefore, in vivo animal studies were evaluated to confirm the prevention of inflammatory bowel disease (IBD) with the treatment of this plant fruits. The IBD was studied in Wistar albino rats by indomethacin (s.c.), acetic acid (i.c.) and dextran sulfate sodium (DSS) induced models. The diseases parameters such as macroscopic, microscopic features, serum biomarkers levels, haematological profile, biochemical and antioxidant levels were determined. The fruit extract (50, 100 and 200mg/kg) treated enterocolitis rats significantly retain their body weight, organ weight, stool consistency, macroscopic score, histology, haematological parameters, antioxidative enzyme levels and also reduce the serum marker levels and myeloperoxidase (MPO) activity compared to prednisolone (2mg/kg) and sulfasalazine (50mg/kg) drugs. In conclusion, regular consumption of P. loureiroi fruit may prevent IBD and strongly support the folklore use of fruit in the treatment of intestinal ailments.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antioxidants; Free radicals; Inflammatory bowel disease; Phoenix loureiroi; Polyphenolics

Mesh:

Substances:

Year:  2017        PMID: 28645006     DOI: 10.1016/j.biopha.2017.06.028

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  1 in total

1.  Toxicity and Antiulcer Properties of Ipomoea wightii (Wall.) Choisy Leaves: An In Vivo Approach Using Wistar Albino Rats.

Authors:  Saikumar Sathyanarayanan; Puthanpura Sasidharan Sreeja; Karuppusamy Arunachalam; Thangaraj Parimelazhagan
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-18       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.